← Leaderboards
Devin R. Burrill
Harvard Medical School
$130,415
Attributed
$130,415
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $52.4K · FY2014–16$100K$75K$50K$25K$0
'14
'15
'16
Funding mix
By agency
NIH$130,415 · 1
By mechanism
F32$130,415 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Allon Moshe Klein$7,807,178
- Kelsey Finn$101,335
- Martin Lafleur$163,296
- Jennifer E Oyler-Yaniv$570,814
- Henry Kyoung$44,020
Others in their field
Top investigators on “Acute Erythroblastic Leukemia”
- Mario Luis Santiago · University Of Colorado Denver$4,134,868
- Stuart H Orkin · Children'S Hospital Boston$3,477,539
- Mitchell J Weiss · Children'S Hospital Of Philadelphia$2,703,168
- Mingjiang Xu · Pennsylvania State Univ Hershey Med Ctr$2,193,292
- Lana X Garmire · University Of Hawaii At Manoa$2,162,207
- Zhijian Qian · University Of Florida$2,131,246
Research focus
Acute Erythroblastic LeukemiaDesignAffinityAnemiaAccountingCytokineAnti-Inflammatory AgentsAutoimmune DiseasesBaseBehaviorAnimalsAffectAnti-InflammatoryBiologicalBlood PlateletsCell LineCell ProliferationCellsCell SurfaceCell Surface ReceptorsCell TypeChimeric ProteinsComplexDrug Kinetics
Grant awards (3)
A synthetic biology approach to targeting erythropoietin-based therapeutics$28,159
F32 · FY2016 · HL · contact PI
A synthetic biology approach to targeting erythropoietin-based therapeutics$52,406
F32 · FY2015 · HL · contact PI
A synthetic biology approach to targeting erythropoietin-based therapeutics$49,850
F32 · FY2014 · HL · contact PI